- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma
Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab in patients with immunotherapy-relapsed/refractory melanoma.